These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 27057126

  • 1. Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy.
    Senol SP, Tiftik EN, Unal S, Akdeniz A, Tasdelen B, Tunctan B.
    J Basic Clin Pharm; 2016 Mar; 7(2):49-59. PubMed ID: 27057126
    [Abstract] [Full Text] [Related]

  • 2. Longitudinal Study on Liver Functions in Patients with Thalassemia Major before and after Deferasirox (DFX) Therapy.
    Soliman A, Yassin M, Al Yafei F, Al-Naimi L, Almarri N, Sabt A, De Sanctis V.
    Mediterr J Hematol Infect Dis; 2014 Mar; 6(1):e2014025. PubMed ID: 24803998
    [Abstract] [Full Text] [Related]

  • 3. Prevalence and Management of Transfusional Iron Overload in Syrian Beta Thalassemia Major Patients Pre and during the Syrian Conflict.
    Touma H, Youssef LA, Al-Salhi L, Ismail Al-Khalil W, AlKeba K.
    Biomed Res Int; 2023 Mar; 2023():8911518. PubMed ID: 37743972
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH, Chen X, Wu CC, Wu KH, Song TS, Weng TF, Hsieh YW, Peng CT.
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [Abstract] [Full Text] [Related]

  • 5. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 6. Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine.
    Hassan MA, Tolba OA.
    Electron Physician; 2016 May; 8(5):2425-31. PubMed ID: 27382454
    [Abstract] [Full Text] [Related]

  • 7. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).
    Antmen B, Karakaş Z, Yeşilipek MA, Küpesiz OA, Şaşmaz İ, Uygun V, Kurtoğlu E, Oktay G, Aydogan G, Akın M, Salcioglu Z, Vergin C, Kazancı EG, Ünal S, Çalışkan Ü, Aral YZ, Türkkan E, Meral Güneş A, Tunç B, Gümrük F, Ayhan AC, Söker M, Koç A, Oymak Y, Ertem M, Timur Ç, Yıldırmak Y, İrken G, Apak H, Biner B, Eren TG, Işık Balcı Y, Koçak Ü, Karasu G, Akkaynak D, Patıroğlu T.
    Eur J Haematol; 2019 Feb; 102(2):123-130. PubMed ID: 30300449
    [Abstract] [Full Text] [Related]

  • 8. Jadenu® Substituting Exjade® in Iron Overloaded β-Thalassemia Major (BTM) Patients: A Preliminary Report of the Effects on the Tolerability, Serum Ferritin Level, Liver Iron Concentration and Biochemical Profiles.
    Yassin MA, Soliman AT, De Sanctis V, Hussein RM, Al-Okka R, Kassem N, Ghasoub R, Basha A, Nashwan AJ, Adel AM.
    Mediterr J Hematol Infect Dis; 2018 Feb; 10(1):e2018064. PubMed ID: 30416696
    [Abstract] [Full Text] [Related]

  • 9. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF.
    Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
    [Abstract] [Full Text] [Related]

  • 10. Iron Chelators, Such as Deferasirox, When Combined With Hydroxyurea, Provide an Additional Benefit of Iron Chelation in Patients Receiving Chronic Transfusion Therapy.
    Manganas K, Delicou S, Xydaki A, Koskinas J.
    Hemoglobin; 2022 Mar; 46(2):114-117. PubMed ID: 36069257
    [Abstract] [Full Text] [Related]

  • 11. Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major.
    Aubart M, Ou P, Elie C, Canniffe C, Kutty S, Delos V, Graffigne C, de Montalembert M, Brousse V.
    J Pediatr Hematol Oncol; 2016 Oct; 38(7):497-502. PubMed ID: 27548334
    [Abstract] [Full Text] [Related]

  • 12. A multicenter cross-sectional study of the quality of life and iron chelation treatment satisfaction of patients with transfusion-dependent β-thalassemia, in routine care settings in Western Greece.
    Goulas V, Kouraklis-Symeonidis A, Manousou K, Lazaris V, Pairas G, Katsaouni P, Verigou E, Labropoulou V, Pesli V, Kaiafas P, Papageorgiou U, Symeonidis A.
    Qual Life Res; 2021 Feb; 30(2):467-477. PubMed ID: 32920766
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M, Arandi N, Haghpanah S, Ansari S, Azarkeyvan A, Bordbar M, Safaei S.
    Hemoglobin; 2015 Feb; 39(5):327-9. PubMed ID: 26114738
    [Abstract] [Full Text] [Related]

  • 14. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 15. Effect of different iron chelation regimens on bone mass in transfusion-dependent thalassemia patients.
    Bordbar M, Haghpanah S, Zekavat OR, Saki F, Bazrafshan A, Bozorgi H.
    Expert Rev Hematol; 2019 Nov; 12(11):997-1003. PubMed ID: 31486684
    [Abstract] [Full Text] [Related]

  • 16. Statural Growth and Prevalence of Endocrinopathies in Relation to Liver Iron Content (LIC) in Adult Patients with Beta Thalassemia Major (BTM) and Sickle Cell Disease (SCD).
    Yassin MA, Soliman AT, De Sanctis V, Abdula MAJ, Riaz LM, Ghori FF, Yousaf A, Nashwan AJ, Abusamaan S, Moustafa A, Kohla S, Soliman DS.
    Acta Biomed; 2018 Feb 16; 89(2-S):33-40. PubMed ID: 29451227
    [Abstract] [Full Text] [Related]

  • 17. Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy.
    Ricchi P, Ammirabile M, Spasiano A, Costantini S, Cinque P, Di Matola T, Prossomariti L.
    Acta Haematol; 2010 Feb 16; 123(2):117-20. PubMed ID: 20068283
    [Abstract] [Full Text] [Related]

  • 18. Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.
    Nolte F, Nückel H, Schmidt B, Geer T, Rubanov O, Hebart H, Jarisch A, Albrecht S, Johr C, Schumann C, Hofmann WK.
    J Cancer Res Clin Oncol; 2018 Aug 16; 144(8):1531-1538. PubMed ID: 29761371
    [Abstract] [Full Text] [Related]

  • 19. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
    Nyffenegger N, Flace A, Doucerain C, Dürrenberger F, Manolova V.
    Int J Mol Sci; 2021 Jan 16; 22(2):. PubMed ID: 33467196
    [Abstract] [Full Text] [Related]

  • 20. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study.
    Scalone L, Mantovani LG, Krol M, Rofail D, Ravera S, Bisconte MG, Borgna-Pignatti C, Borsellino Z, Cianciulli P, Gallisai D, Prossomariti L, Stefàno I, Cappellini MD.
    Curr Med Res Opin; 2008 Jul 16; 24(7):1905-17. PubMed ID: 18507891
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.